AstraZeneca offers Farxiga, Airsupra discounts on new DTC sitenews2025-09-26T17:58:25+00:00September 26th, 2025|Endpoints News|
Patient groups push abandoned rare disease gene therapy toward clinical trialnews2025-09-26T14:32:48+00:00September 26th, 2025|Endpoints News|
White House weighs broad drug pricing announcementnews2025-09-25T21:10:12+00:00September 25th, 2025|Endpoints News|
Two new ARPA-H programs aim to boost genetic medicine accessnews2025-09-25T20:32:40+00:00September 25th, 2025|Endpoints News|
FDA approves Lilly’s oral SERD in second-line breast cancernews2025-09-25T19:23:52+00:00September 25th, 2025|Endpoints News|
Biogen calls it quits on AAV gene therapy, againnews2025-09-25T18:33:19+00:00September 25th, 2025|Endpoints News|
Virtual team of researchers, advocates try to break 40-year logjam in osteosarcomanews2025-09-25T15:15:19+00:00September 25th, 2025|Endpoints News|
UK government reveals £50M R&D fund as it attempts to assuage drugmakers’ concerns news2025-09-25T13:59:06+00:00September 25th, 2025|Endpoints News|
PepGen seeks funds on the back of early-stage data in muscle wasting diseasenews2025-09-25T10:28:11+00:00September 25th, 2025|Endpoints News|
Hansa’s kidney transplant drug succeeds in Phase 3 trial in USnews2025-09-25T08:36:14+00:00September 25th, 2025|Endpoints News|
